Sichenzia Ross Ference Kesner LLP Represents Tonix Pharmaceuticals in $5.2 Million Public Offering
Press Release – New York, NY – November 1, 2016 – Nationally recognized securities and corporate law firm Sichenzia Ross Ference Kesner LLP announced today that it represented Tonix Pharmaceuticals Holding Corp. (NASDAQ “TNXP”), a developer of next-generation medicines for common disorders of the central nervous system, with its lead program focusing on post traumatic stress disorder, in an underwritten public offering of 9,500,000 units, with each unit consisting of one (1) share of common stock and a warrant to purchase one-half (0.5) of a share of common stock. The Units were sold at a public offering price of $0.55 per Unit, for aggregate gross proceeds of $5.2 million. Dawson James Securities, Inc. acted as the sole book-running manager for the offering.
The Sichenzia Ross Ference Kesner LLP team was led by partners Marc J. Ross and James M. Turner and associate S. Ashley Jaber.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Medical Marijuana Dispensary Business Project 1493, LLC Announces Share Exchange Agreement with Public Entity & Simultaneous $3.3 Million PIPE Financing - June 16, 2017
- Sichenzia Ross Ference Kesner LLP Represents Immuron Limited on $6.1M IPO and NASDAQ listing - June 15, 2017
- Sichenzia Ross Ference Kesner LLP Represents Joseph Gunnar, and Fordham Financial Management in $6.6 Registered Direct offering of Ampio Pharmaceuticals, Inc. - June 8, 2017